Dianthus Therapeutics, Inc. Common Stock DNTH
i
Market datapartial · fetched 2026-11-04T04:38:03.255Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-04T00:00:50.054005668Z
FundamentalsAlpha Vantage · unavailable
Dianthus Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 111.87 | 144.2% | 39.4% | 69.06 | 112.0% | 18.8% |
| 25Δ | 98.14 | 104.8% | 22.7% | 73.64 | 86.5% | 13.2% |
| 30Δ | 92.07 | 84.6% | 15.4% | 76.37 | 72.8% | 10.0% |
| 35Δ | 88.88 | 76.5% | 12.0% | 78.38 | 63.7% | 7.8% |
| 40Δ | 86.82 | 74.4% | 10.1% | 80.25 | 56.5% | 5.9% |
| 45Δ | 84.81 | 72.8% | 8.3% | 81.54 | 56.7% | 5.2% |
| 50Δ | 83.15 | 75.5% | 7.4% | 82.82 | 57.0% | 4.5% |
| 55Δ | 81.48 | 78.2% | 6.6% | 84.11 | 57.3% | 3.8% |
| 60Δ | 79.81 | 80.6% | 5.7% | 85.44 | 57.2% | 3.1% |
| 65Δ | 78.00 | 79.7% | 4.7% | 86.87 | 56.7% | 2.6% |
| 70Δ | 76.20 | 78.9% | 3.8% | 88.31 | 56.1% | 2.0% |
| 75Δ | 74.28 | 78.4% | 2.9% | 89.74 | 55.5% | 1.5% |
| 80Δ | 72.12 | 78.3% | 2.3% | 91.95 | 56.4% | 1.1% |
20Δ
- Pseudo strike
- 111.87
- IV
- 144.2%
- B/E move
- 39.4%
- Pseudo strike
- 69.06
- IV
- 112.0%
- B/E move
- 18.8%
25Δ
- Pseudo strike
- 98.14
- IV
- 104.8%
- B/E move
- 22.7%
- Pseudo strike
- 73.64
- IV
- 86.5%
- B/E move
- 13.2%
30Δ
- Pseudo strike
- 92.07
- IV
- 84.6%
- B/E move
- 15.4%
- Pseudo strike
- 76.37
- IV
- 72.8%
- B/E move
- 10.0%
35Δ
- Pseudo strike
- 88.88
- IV
- 76.5%
- B/E move
- 12.0%
- Pseudo strike
- 78.38
- IV
- 63.7%
- B/E move
- 7.8%
40Δ
- Pseudo strike
- 86.82
- IV
- 74.4%
- B/E move
- 10.1%
- Pseudo strike
- 80.25
- IV
- 56.5%
- B/E move
- 5.9%
45Δ
- Pseudo strike
- 84.81
- IV
- 72.8%
- B/E move
- 8.3%
- Pseudo strike
- 81.54
- IV
- 56.7%
- B/E move
- 5.2%
50Δ
- Pseudo strike
- 83.15
- IV
- 75.5%
- B/E move
- 7.4%
- Pseudo strike
- 82.82
- IV
- 57.0%
- B/E move
- 4.5%
55Δ
- Pseudo strike
- 81.48
- IV
- 78.2%
- B/E move
- 6.6%
- Pseudo strike
- 84.11
- IV
- 57.3%
- B/E move
- 3.8%
60Δ
- Pseudo strike
- 79.81
- IV
- 80.6%
- B/E move
- 5.7%
- Pseudo strike
- 85.44
- IV
- 57.2%
- B/E move
- 3.1%
65Δ
- Pseudo strike
- 78.00
- IV
- 79.7%
- B/E move
- 4.7%
- Pseudo strike
- 86.87
- IV
- 56.7%
- B/E move
- 2.6%
70Δ
- Pseudo strike
- 76.20
- IV
- 78.9%
- B/E move
- 3.8%
- Pseudo strike
- 88.31
- IV
- 56.1%
- B/E move
- 2.0%
75Δ
- Pseudo strike
- 74.28
- IV
- 78.4%
- B/E move
- 2.9%
- Pseudo strike
- 89.74
- IV
- 55.5%
- B/E move
- 1.5%
80Δ
- Pseudo strike
- 72.12
- IV
- 78.3%
- B/E move
- 2.3%
- Pseudo strike
- 91.95
- IV
- 56.4%
- B/E move
- 1.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 70.04% | |
| 70.98% | |
| 70.06% | |
| 70.90% | |
| 70.20% | |
| 71.49% | |
| 70.52% | |
| 72.31% | |
| 71.06% | |
| 70.22% |
Biotechnology
DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha…
More →DRUG
Bright Minds Biosciences Inc. (DRUG) is a forward-thinking clinical-stage biotechnology firm specializing in the development of groundbreaking therapies for central nervous system…
More →DSGN
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad,…
More →DTIL
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
More →DYN
Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The…
More →EDIT
Description unavailable
More →